Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573451 | 0.84 | SMN1; SMN2 (0.59) | GDAKDM4EGAAKMT2AMEN1 | |
| SCHEMBL442818 | 0.84 | NOS1 (0.45) | GDAKDM4EGAAKMT2AMEN1 | |
| SCHEMBL12227604 | 0.84 | GDA (0.45) | GDAKDM4EGAAKMT2AMEN1 | |
| SCHEMBL12227599 | 0.83 | GDA (0.45) | GDAKDM4EGAAKMT2AMEN1 | |
| SCHEMBL1398291 | 0.81 | GDA (0.42) | GDAKDM4EGAAFGFR1ALDH1A1 | |
| SCHEMBL28469810 | 0.80 | GDA (0.42) | GDAKDM4EGAAKMT2AMEN1 | |
| SCHEMBL28969 | 0.80 | PDPK1 (0.41) | GDAKDM4EGAAALDH1A1LMNA | |
| SCHEMBL14260671 | 0.80 | GDA (0.39) | GDAKDM4EGAAALDH1A1LMNA | |
| SCHEMBL1425017 | 0.79 | ADORA2A (0.52) | KDM4EKMT2AMEN1TSHRADORA3 | |
| SCHEMBL12227601 | 0.77 | RAB9A (0.51) | KDM4EKMT2AMEN1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115367745-B | Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2023-11-24 | — | — | CN | claimed |
| CN-113149988-B | Preparation method and application of ganciclovir | 海南锦瑞制药有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115367726-A | Oxygen-doped titanium nitride hybridized and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2022-11-22 | — | — | CN | claimed |
| CN-115367745-A | Tungsten-containing substance hybrid and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2022-11-22 | — | — | CN | claimed |
| WO-2021238912-A1 | TRANSITION METAL COMPOUND-HYBRIDIZED AND NITROGEN-DOPED POROUS CARBON MATERIAL AND PREPARATION METHOD THEREFOR | 北京化工大学 | 2021-12-02 | — | — | WO | claimed |
| CN-113149988-A | Ganciclovir preparation method and application | 海南锦瑞制药有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-111892047-A | Vanadium nitride hybrid and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2020-11-06 | — | — | CN | claimed |
| CN-107074911-B | Peptide nucleic acid monomers and oligomers | 优基艾森斯股份公司 | 2020-11-03 | — | — | CN | claimed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-6808716-B2 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2004-10-26 | — | — | US | claimed |
| WO-2004089329-A2 | TOPICAL COMPOSITIONS COMPRISING N-ACETYLAMINO ACIDS OR RELATED N-ACETYL COMPOUNDS | YU RUEY J (US) | 2004-10-21 | — | — | WO | claimed |
| US-20030198656-A1 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2003-10-23 | — | — | US | claimed |
| US-5780607-A | PYRANOSYL NUCLEOSIDE MONOMER UNITS CONNECTED BY AMIDE LINKAGES | HOFFMANN-LA ROCHE INC. (US) | 1998-07-14 | — | — | US | claimed |
| WO-1997014709-A1 | ANTISENSE OLIGOMERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-24 | — | — | WO | claimed |
| CN-1128269-A | Oligoribonucleotides with amide backbone | HOFFMANN LA ROCHE (CH) | 1996-08-07 | — | — | CN | claimed |
| EP-0714907-A1 | Oligoribonucleotides with amide backbone | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-05 | — | — | EP | claimed |
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | claimed |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-3840748-B1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582656-B2 | Nucleotide analogues | R.G.C.C. Holdings AG (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20250320430-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-10-16 | — | — | US | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-4125912-B1 | COMPOUNDS FOR THE IN VITRO INHIBITION OF THE RNA-DEPENDENT RNA POLYMERASE OF CORONAVIRUSES | R G C C HOLDINGS AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| CN-120309613-A | Amplification preparation method of ganciclovir | 湖北天义药业有限公司 | 2025-07-15 | — | — | CN | disclosed |
| WO-2025134877-A1 | KIT AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2025-06-26 | — | — | WO | disclosed |
| US-20250129308-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-04-24 | — | — | US | disclosed |
| CN-119404296-A | Semiconductor processing liquid, method for processing object to be processed, and method for manufacturing electronic device | 富士胶片株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20250017209-A1 | COMPOSITION, MANUFACTURING METHOD FOR SEMICONDUCTOR ELEMENT, AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE | FUJIFILM CORPORATION (JP) | 2025-01-16 | — | — | US | disclosed |
| US-20240400942-A1 | CLEANING COMPOSITION AND CLEANING METHOD OF SEMICONDUCTOR SUBSTRATE | FUJIFILM CORPORATION (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-118922917-A | Composition, method for manufacturing semiconductor element, and method for cleaning semiconductor substrate | 富士胶片株式会社 | 2024-11-08 | — | — | CN | disclosed |
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024166627-A1 | SEMICONDUCTOR PROCESSING LIQUID, PROCESSING METHOD FOR OBJECT TO BE PROCESSED, AND MANUFACTURING METHOD FOR ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-08-15 | — | — | WO | disclosed |
| WO-2024122300-A1 | PROCESSING LIQUID, CLEANING METHOD FOR OBJECT TO BE PROCESSED, AND METHOD FOR PRODUCING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-06-13 | — | — | WO | disclosed |
| US-20240117278-A1 | TREATMENT LIQUID, CLEANING METHOD OF SEMICONDUCTOR SUBSTRATE, AND MANUFACTURING METHOD OF SEMICONDUCTOR ELEMENT | FUJIFILM CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| CN-117551100-A | Preparation method of (S) -9- [3- (4, 4' -dimethoxy trityl) -2-hydroxypropyl ] -N2-acetyl guanine | 苏州诺维康生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20240026254-A1 | CLEANING LIQUID FOR SEMICONDUCTOR SUBSTRATE | FUJIFILM CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240018442-A1 | CLEANING LIQUID FOR SEMICONDUCTOR SUBSTRATE AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE | FUJIFILM CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| WO-2024014224-A1 | SEMICONDUCTOR PROCESSING LIQUID, METHOD FOR PROCESSING OBJECT TO BE PROCESSED, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024014220-A1 | SEMICONDUCTOR PROCESSING LIQUID, PROCESSING METHOD FOR OBJECT TO BE PROCESSED, AND MANUFACTURING METHOD FOR ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-01-18 | — | — | WO | disclosed |
| CN-115367745-B | Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023182142-A1 | COMPOSITION, SEMICONDUCTOR-ELEMENT MANUFACTURING METHOD, AND SEMICONDUCTOR-SUBSTRATE WASHING METHOD | 富士フイルム株式会社 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023176708-A1 | CLEANING COMPOSITION AND SEMICONDUCTOR SUBSTRATE CLEANING METHOD | 富士フイルム株式会社 | 2023-09-21 | — | — | WO | disclosed |
| CN-113149988-B | Preparation method and application of ganciclovir | 海南锦瑞制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-113149988-B | Preparation method and application of ganciclovir | 海南锦瑞制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230118992-A1 | NUCLEOTIDE ANALOGUES | R.G.C.C.Holdings AG (CH) | 2023-04-20 | — | — | US | disclosed |
| CN-115819483-A | Nucleoside derivatives for treating cancer and use thereof | 南京知和医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4125912-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022255220-A1 | PROCESSING SOLUTION, METHOD FOR CLEANING SEMICONDUCTOR SUBSTRATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR ELEMENT | 富士フイルム株式会社 | 2022-12-08 | — | — | WO | disclosed |
| CN-115367745-A | Tungsten-containing substance hybrid and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2022-11-22 | — | — | CN | disclosed |
| US-11505815-B2 | Compositions and methods related to non-templated enzymatic nucleic acid synthesis | NUCLERA NUCLEICS, LTD. (GB) | 2022-11-22 | — | — | US | disclosed |
| CN-115367726-A | Oxygen-doped titanium nitride hybridized and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022202287-A1 | SEMICONDUCTOR SUBSTRATE CLEANING SOLUTION, AND METHOD FOR CLEANING SEMICONDUCTOR SUBSTRATE | 富士フイルム株式会社 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022168687-A1 | SEMICONDUCTOR SUBSTRATE CLEANING SOLUTION | 富士フイルム株式会社 | 2022-08-11 | — | — | WO | disclosed |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021238912-A1 | TRANSITION METAL COMPOUND-HYBRIDIZED AND NITROGEN-DOPED POROUS CARBON MATERIAL AND PREPARATION METHOD THEREFOR | 北京化工大学 | 2021-12-02 | — | — | WO | disclosed |
| WO-2021191236-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| CN-113149988-A | Ganciclovir preparation method and application | 海南锦瑞制药有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113149988-A | Ganciclovir preparation method and application | 海南锦瑞制药有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-108467396-B | Ganciclovir preparation method | 安徽海康药业有限责任公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3840748-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3229610-B1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-111892047-A | Vanadium nitride hybrid and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2020-11-06 | — | — | CN | disclosed |
| CN-107074911-B | Peptide nucleic acid monomers and oligomers | 优基艾森斯股份公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3710461-A1 | NUCLEOTIDE DERIVATIVES CONTAINING AMINE MASKED MOIETIES AND THEIR USE IN A TEMPLATED AND NON-TEMPLATED ENZYMATIC NUCLEIC ACID SYNTHESIS | Nuclera Nucleics Ltd (GB) | 2020-09-23 | — | — | EP | disclosed |
| CN-111344296-A | Nucleotide derivatives containing amine-masked moieties and their use in templated and non-templated enzymatic nucleic acid synthesis | 核酸有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| WO-2020041562-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2020-02-27 | — | — | WO | disclosed |
| CN-108912122-B | Method for synthesizing acyclovir and ganciclovir by carbon-hydrogen bond activation | 信阳师范学院 | 2020-01-07 | — | — | CN | disclosed |
| US-20190144905-A1 | Novel Use | Nuclera Nucleics Ltd. (GB) | 2019-05-16 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| EP-1525209-B1 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2794628-B1 | 4'-AZIDO-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9408863-B2 | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2006102970-A9 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2016-05-26 | — | — | WO | disclosed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-1730298-B1 | SPECIFIC SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | EPFL ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-104610261-A | Preparation method of ganciclovir intermediate | HUBEI YITAI PHARMACEUTICAL CO LTD | 2015-05-13 | — | — | CN | disclosed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2014-12-18 | — | — | US | disclosed |
| EP-2794628-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8859749-B2 | Modified short interfering RNA | QIAGEN GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| EP-2731433-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8569476-B2 | Method for preparing oligonucleotide | Suzhou Ribo Life Science Co., Ltd. (CN) | 2013-10-29 | — | — | US | disclosed |
| EP-2619215-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013092447-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| EP-2380896-B1 | A METHOD FOR PREPARING OLIGONUCLEOTIDE | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2013009737-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| CN-102702199-A | Method for preparing ganciclovir | HUBEI GEDIAN RENFU PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | disclosed |
| WO-2012040124-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION | 2012-03-15 | — | — | US | disclosed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2380896-A1 | A METHOD FOR PREPARING OLIGONUCLEOTIDE | Suzhou Ribo Life Science Co., Ltd (CN) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237786-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDE | SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) | 2011-09-29 | — | — | US | disclosed |
| US-7662798-B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| WO-2005016268-A3 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RES INC (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | AJINOMOTO CO., INC. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1550665-A1 | A process for the production of purine nucleoside compounds | Ajinomoto Co., Inc. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1535923-A1 | Synthesis of acyclic nucleoside derivatives | Medivir Aktiebolag (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-0882050-B2 | PROCESS FOR PREPARING PURINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | EP | disclosed |
| EP-1131323-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2005-04-27 | — | — | EP | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1414822-B1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-6808716-B2 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2004-10-26 | — | — | US | disclosed |
| WO-2004089329-A2 | TOPICAL COMPOSITIONS COMPRISING N-ACETYLAMINO ACIDS OR RELATED N-ACETYL COMPOUNDS | YU RUEY J (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | BANK OF NEW YORK, THE | 2004-07-29 | — | — | US | disclosed |
| EP-1414822-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| CN-1137892-C | Preparation of N-9 substituted guanine compound | - | 2004-02-11 | — | — | CN | disclosed |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-02-05 | — | — | US | disclosed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | AJINOMOTO CO., INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030198656-A1 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2003-10-23 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| US-6579976-B2 | Producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids by allowing O-thiocarbonyl derivatives or halogenated derivatives in the sugar-moiety react with hypophosphorous acids or salts | AJINOMOTO CO., INC. (JP) | 2003-06-17 | — | — | US | disclosed |
| WO-2003002564-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| CN-1091445-C | Internmediate of anti viral medicine, their preparation and use | HUBEI PROV MEDICINE INDUSTRY I (CN) | 2002-09-25 | — | — | CN | disclosed |
| EP-0882050-B1 | PROCESS FOR PREPARING PURINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2002-08-28 | — | — | EP | disclosed |
| US-20020045744-A1 | PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6340756-B1 | VIRICIDES | SYNTEX (U.S.A.) INC. | 2002-01-22 | — | — | US | disclosed |
| EP-0728757-B1 | Process for producing purine derivatives | AJINOMOTO KK (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-1131323-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 2001-09-12 | — | — | EP | disclosed |
| CN-1301702-A | Internmediate of anti viral medicine, their preparation and use | HUBEI PROV MEDICINE INDUSTRY I (CN) | 2001-07-04 | — | — | CN | disclosed |
| US-6245910-B1 | Process for producing purine derivatives | AJINOMOTO CO., INC. (JP) | 2001-06-12 | — | — | US | disclosed |
| CN-1064683-C | Process for preparing purine derivatives | HOFFMANN LA ROCHE (CH) | 2001-04-18 | — | — | CN | disclosed |
| US-6218568-B1 | REACTING 1-ARALKYLOXY-3-HALO-2-PROPANOL WITH METHOXYMETHYL ALKANOATE IN APROTIC SOLVENT IN THE PRESENCE OF A CATALYST TO PRODUCE 1-ARALKYLOXY-3-HALO-2-(ALKANOYLOXY)METHOXYPROPANE AND TREATING THE PRODUCT WITH ALKALI METAL ALKANOATE | SYNTEX (U.S.A.) INC. | 2001-04-17 | — | — | US | disclosed |
| US-6215017-B1 | 1-ARALKYLOXY-3-ACYLOXY-2-(ACYLOXY)METHOXYPROPANE DERIVATIVE; CHEMICAL INTERMEDIATES FOR VIRICIDE GANCICLOVIR | SYNTEX (U.S.A.) INC. | 2001-04-10 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| US-6087497-A | DEBENZYLATION OF PURINE TO FORM VIRICIDES | AJINOMOTO CO., INC. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0999218-A1 | Process for producing nucleoside derivatives | Ajinomoto Co., Inc. (JP) | 2000-05-10 | — | — | EP | disclosed |
| CN-1051084-C | Preparation of N-9 substituted guanine compounds | HOFFMANN LA ROCHE (CH) | 2000-04-05 | — | — | CN | disclosed |
| US-6040446-A | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | SYNTEX (U.S.A.) INC. (US) | 2000-03-21 | — | — | US | disclosed |
| CN-1246477-A | Preparation of N-9 substituted guanine compound | HOFFMANN LA ROCHE (CH) | 2000-03-08 | — | — | CN | disclosed |
| WO-2000008025-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0961775-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5942617-A | Process for producing purine derivatives | AJINOMOTO CO., INC. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0704445-B1 | Preparation of N-9 substituted guanine compounds | HOFFMANN LA ROCHE (CH) | 1999-04-21 | — | — | EP | disclosed |
| CN-1212693-A | Process for preparing purine derivatives | HOFFMANN LA ROCHE (CH) | 1999-03-31 | — | — | CN | disclosed |
| EP-0882050-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |
| US-5831092-A | Process for producing purine derivatives | AJINOMOTO CO., INC. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5780607-A | PYRANOSYL NUCLEOSIDE MONOMER UNITS CONNECTED BY AMIDE LINKAGES | HOFFMANN-LA ROCHE INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998016184-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0827960-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997027198-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| US-5648489-A | PREPARING 9-((1,3-DIHYDROXY-2-PROPOXY)METHYL)GUANINE FROM A PROTECTED GUANINE AND 2-ACETOXYMETHOXY-1,3-DIACETOXYPROPANE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997014709-A1 | ANTISENSE OLIGOMERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-24 | — | — | WO | disclosed |
| US-5583225-A | REACTING N2, N9-DIPROTECTED GUANINE WITH DIACETOXYPROPANE IN THE PRESENCE OF A MIXTURE OF AN ACID AND ACETIC ANHYDRIDE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565565-A | Preparation of N-9 substituted guanine compounds | SYNTEX (U.S.A.) INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0728757-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1996-08-28 | — | — | EP | disclosed |
| CN-1120044-A | Preparation of N-9 substituted guanine compounds | HOFFMANN LA ROCHE (US) | 1996-04-10 | — | — | CN | disclosed |
| EP-0704445-A1 | Preparation of N-9 substituted guanine compounds | F. Hoffmann-La Roche AG (CH) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995011909-A1 | PEPTIDE-BASED NUCLEIC ACID SURROGATES | CASE WESTERN RESERVE UNIVERSITY (US) | 1995-05-04 | — | — | WO | disclosed |
| US-5157120-A | Guanine derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0243670-B1 | PURINE AND PYRIMIDINE COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| EP-0049072-B1 | GUANINE COMPOUNDS AND THEIR USE FOR THE PREPARATION OF ANTI-VIRAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4868187-A | Anti-viral N-substituted pyrimidines | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0243670-A1 | Purine and pyrimidine compounds and their use as anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1987-11-04 | — | — | EP | disclosed |
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | disclosed |
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (26 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RNGTT, NSUN2, NSUN3 | GDA 702/4885KDM4E 561/4885GAA 333/4885 |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | GDA 119/4885KDM4E 2276/4885GAA 290/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | GDA 119/4885KDM4E 2276/4885GAA 290/4885 |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | TPMT, P2RY13, TST | GDA 1625/4885KDM4E 3987/4885GAA 1300/4885 |
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | TGFB1, TGFBR1, TGFB2 | GDA 4638/4885KDM4E 1077/4885GAA 1463/4885 |
| US-11505815-B2 | Compositions and methods related to non-templated enzymatic nucleic acid synthesis | RNGTT, DUT, PNP | GDA 83/4885KDM4E 1072/4885GAA 148/4885 |
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | RNGTT, DOHH, NT5C3B | GDA 228/4885KDM4E 2255/4885GAA 1356/4885 |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | RNMT, POLRMT, RNGTT | GDA 69/4885KDM4E 4011/4885GAA 1180/4885 |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | GDA 104/4885KDM4E 3367/4885GAA 2820/4885 |
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | GDA 1238/4885KDM4E 2497/4885GAA 2838/4885 |
| US-12582656-B2 | Nucleotide analogues | RNGTT, PNP, RNMT | GDA 457/4885KDM4E 2309/4885GAA 2381/4885 |
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | PNP, NUDT1, UMPS | GDA 66/4885KDM4E 3453/4885GAA 932/4885 |
| US-20230118992-A1 | NUCLEOTIDE ANALOGUES | PNP, NUDT1, RNGTT | GDA 114/4885KDM4E 2971/4885GAA 1761/4885 |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | GDA 578/4885KDM4E 4410/4885GAA 2583/4885 |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | GDA 4655/4885KDM4E 1114/4885GAA 1486/4885 |
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NT5C3B, PNP, SLC29A1 | GDA 102/4885KDM4E 2444/4885GAA 366/4885 |
| US-20020045744-A1 | PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES | RNGTT, OSGEP, PNP | GDA 213/4885KDM4E 2751/4885GAA 1060/4885 |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | GDA 671/4885KDM4E 4093/4885GAA 907/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | GDA 578/4885KDM4E 4410/4885GAA 2583/4885 |
| US-20250017209-A1 | COMPOSITION, MANUFACTURING METHOD FOR SEMICONDUCTOR ELEMENT, AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE | SPOUT1, SRM, SMOX | GDA 62/4885KDM4E 2023/4885GAA 164/4885 |
| US-20190144905-A1 | Novel Use | DUT, RNGTT, MTAP | GDA 158/4885KDM4E 1047/4885GAA 187/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | GDA 445/4885KDM4E 4268/4885GAA 2738/4885 |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | SI, POLL, ME1 | GDA 153/4885KDM4E 1834/4885GAA 306/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | GDA 488/4885KDM4E 3958/4885GAA 209/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | GDA 656/4885KDM4E 4031/4885GAA 919/4885 |
| US-20110237786-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDE | POLRMT, POLR2H, RNGTT | GDA 3894/4885KDM4E 4354/4885GAA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.